OtherCommentary
Conducting Clinical Risk Assessments for Visible Particulate Matter in Parenteral Preparations
John D Ayres
PDA Journal of Pharmaceutical Science and Technology August 2018, pdajpst.2018.008615; DOI: https://doi.org/10.5731/pdajpst.2018.008615
John D Ayres
Eli Lilly and Company
In This Issue
PDA Journal of Pharmaceutical Science and Technology
Vol. 79, Issue 3
May/June 2025
Conducting Clinical Risk Assessments for Visible Particulate Matter in Parenteral Preparations
John D Ayres
PDA Journal of Pharmaceutical Science and Technology Aug 2018, pdajpst.2018.008615; DOI: 10.5731/pdajpst.2018.008615
Jump to section
Related Articles
- No related articles found.